Frontlight ResearchEarly access
CompletedNo phase
Alwide Plus China Post-market Clinical Investigation
Key facts
- Who runs it
- Shanghai MicroPort CardioFlow Medtech Co., Ltd.
- Where
- China4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 75 people enrolled
- Started
- 3 Jan 2025
- Ended
- 4 Nov 2025
- Type of study
- Observational
- Record updated
- 26 December 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Age≥18 years old
- Severe aortic stenosis verified by echocardiogram: mean transvalvular gradient≥40mmHg (1mmHg=0.133kPa), or peak aortic jet velocity≥4m/s, or aortic valve area (AVA) ≤ 1.0cm2 (or AVA index≤ 0.6cm2/m2)
- Patients, who can understand the clinical investigation purpose, voluntary agree and sign the informed consent form, and willing to comply with relevant trial assessments and clinical follow up
Who cannot take part
- Acute myocardial infarction (MI) occurred in the last 30 days before the treatment;
- Unable to receive anticoagulation or antiplatelet therapy;
- Patients who participated in other clinic trials of drugs or medical device before being enrolled for which the primary endpoint follow up duration has not been reached;
- Allergy to nitinol or sensitive contrast media;
- Active bacterial endocarditis or other active infection may affect the procedure;
- vulnerable individuals who are unable to give informed consent/ unable to fully understand all aspects of the investigation or Severe incapacitating Alzheimer's disease;
- Serious left ventricular dysfunction with left ventricular ejection fraction (LVEF) <20%
- Aortic valve anatomy or lesion unsuitable or not necessary for balloon pre-dilation during the TAVR procedure
- TAVR procedure in trans-apical access
- Pre-implanted mechanical or bioprosthetic valve at the aortic valve position
- LVOT obstruction
- Echocardiographic evidence of intracardiac mass, thrombus or neoplasm;
- Aortic valve anatomy , lesion, or other situation unsuitable for the prosthesis valve implantation as assessed by the investigator team;
- Life expectancy > 12 months;
- Investigators determined that patients have poor compliance and can't complete the study as required
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a prospective, single-arm, multi-center, post-market registry study conducted in China. The purpose is to evaluate the safety and effectiveness of the AlwideTM Plus balloon catheter for pre-dilatation of the aortic valve during TAVR in the real-world setting.
The group in the trial
- Alwide Plus
Paitents perfomed TAVR and have Alwlide Plus Balloon Catheter pre-dilaton or post-dilation
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Multicenter, Post-market Clinical Investigation to Evaluate the Pre-dilation Safety and Effectiveness of Alwide Plus Balloon Catheter of MicroPort CardioFlow in Transcatheter Aortic Valve Replacement
- Record updated
- 26 December 2025